Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

One visit, two shots: study tests combining RSV and shingles vaccines

NCT ID NCT06890416

Vaccine Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether giving the RSV vaccine (Abrysvo) and the shingles vaccine (Shingrix) at the same doctor's visit is safe and works as well as giving them separately. About 526 adults aged 50 and older took part. Researchers measured immune responses and tracked side effects like pain, fatigue, and fever for up to 4 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
RSV prefusion F subunit vaccine (Abrysvo) and herpes zoster subunit vaccine (Shingrix)
What this could lead to
If successful, this could show that getting both vaccines at the same visit is safe and effective, simplifying protection against RSV and shingles for older adults.
What could go wrong
This is a completed Phase 3 study, but results are not yet published. Combining vaccines may cause more side effects or slightly lower immune responses than giving them separately.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

526 people

The number who actually took part.

Started

Apr 2025

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria • Male and female participants 50 years of age and older who are healthy or with stable chronic medical conditions Exclusion Criteria * Current clinically suspected or polymerase chain reaction (PCR)-confirmed ongoing episode of HZ and/or history of clinically suspected or PCR-confirmed HZ within the past 12 months. * Prior history of any subtype of Guillain Barré syndrome of any etiology. * Serious chronic disorder, including metastatic malignancy, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the participant from participating in the study. * Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination, and medication list * Previous vaccination with any licensed or investigational RSV vaccine at any time prior to enrollment, or planned receipt of a nonstudy RSV vaccine during study participation. * Previous vaccination with any licensed recombinant adjuvant zoster vaccine (Shingrix) at any time prior to enrollment, or planned receipt of a nonstudy licensed VZV vaccine (Shingrix) during study participation. * History of previous vaccination with live HZ vaccine (Zostavax) in the last 2 years from enrollment, or planned receipt through study participation. * Previous vaccination with any investigational VZV vaccine at any time prior to enrollment, or planned receipt of a nonstudy investigational VZV vaccine during study participation. * Individuals who receive chronic systemic treatment with immunosuppressive therapy, including cytotoxic agents, immunosuppressive monoclonal antibodies, systemic corticosteroids (defined as ≥20 mg/day of prednisone or equivalent for ≥14 days), eg, for cancer or an autoimmune disease, or radiotherapy, from 60 days before study intervention administration, or planned receipt throughout the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Respiratory syncytial virus (RSV) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

herpes zoster prevention target respiratory syncytial virus infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Respiratory syncytial virus (RSV)

Contacts and locations

Locations

  • AMR Clinical

    Mobile, Alabama, 36608, United States

  • Alliance for Multispecialty Research, LLC

    Doral, Florida, 33172, United States

  • Central Research Associates

    Birmingham, Alabama, 35205, United States

  • Centricity Research Columbus Georgia Multispecialty

    Columbus, Georgia, 31904, United States

  • Centricity Research Columbus Ohio Multispecialty

    Columbus, Ohio, 43213, United States

  • Clinical Neuroscience Solutions Inc.

    Memphis, Tennessee, 38119, United States

  • Clinical Research Atlanta

    Stockbridge, Georgia, 30281, United States

  • Clinical Research Professionals

    Chesterfield, Missouri, 63005, United States

  • Clinical Research Puerto Rico

    San Juan, 00909, Puerto Rico

  • DM Clinical Research - Bellaire

    Houston, Texas, 77081, United States

  • DM Clinical Research - Philadelphia

    Philadelphia, Pennsylvania, 19107, United States

  • DM Clinical Research - Sugar Land

    Sugar Land, Texas, 77478, United States

  • De La Cruz Research Center, LLC

    Miami, Florida, 33184, United States

  • DelRicht Research

    New Orleans, Louisiana, 70115, United States

  • Diablo Clinical Research, Inc.

    Walnut Creek, California, 94598, United States

  • IMA Clinical Research San Antonio

    San Antonio, Texas, 78229, United States

  • IMA Clinical Research Warren

    Warren Township, New Jersey, 07059, United States

  • Jadestone Clinical Research

    Silver Spring, Maryland, 20904, United States

  • Kaiser Permanente

    Los Angeles, California, 90027, United States

  • Medical Affiliated Research Center

    Huntsville, Alabama, 35801, United States

  • NYU Langone Health

    New York, New York, 10016, United States

  • Oakland Medical Research

    Troy, Michigan, 48085, United States

  • Optimal Research

    Peoria, Illinois, 61614, United States

  • Proactive Clinical Research,LLC

    Fort Lauderdale, Florida, 33308, United States

  • SMS Clinical Research

    Mesquite, Texas, 75149, United States

  • Synexus Clinical Research US, Inc.

    Chicago, Illinois, 60602, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.